NCT00111696View on ClinicalTrials.gov

Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

August 31, 2007

Study Completion Date

November 30, 2007

Conditions
Malignant Melanoma
Interventions
BIOLOGICAL

MEDI-522

Supplied at a concentration of 50 mg/mL in both 2 mL and 10mL vials

Trial Locations (1)

15213

University Of Pittsburgh Cancer Institute, Pittsburgh

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY

NCT00111696 - Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma | Biotech Hunter | Biotech Hunter